Voya Investment Management LLC Has $1.93 Million Stock Holdings in CG Oncology, Inc. $CGON

Voya Investment Management LLC increased its stake in CG Oncology, Inc. (NASDAQ:CGON) by 217.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 47,986 shares of the company’s stock after acquiring an additional 32,877 shares during the quarter. Voya Investment Management LLC owned about 0.06% of CG Oncology worth $1,933,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Tower Research Capital LLC TRC increased its position in CG Oncology by 159.2% during the 2nd quarter. Tower Research Capital LLC TRC now owns 6,982 shares of the company’s stock valued at $182,000 after purchasing an additional 4,288 shares during the period. E Fund Management Co. Ltd. bought a new stake in shares of CG Oncology in the 2nd quarter valued at $232,000. Rafferty Asset Management LLC increased its position in shares of CG Oncology by 12.3% during the second quarter. Rafferty Asset Management LLC now owns 80,228 shares of the company’s stock worth $2,086,000 after buying an additional 8,802 shares during the period. Rosalind Advisors Inc. bought a new position in CG Oncology during the second quarter worth $5,017,000. Finally, Opaleye Management Inc. lifted its holdings in CG Oncology by 62.2% in the second quarter. Opaleye Management Inc. now owns 266,000 shares of the company’s stock valued at $6,916,000 after buying an additional 102,012 shares during the period. 26.56% of the stock is currently owned by institutional investors.

Insider Buying and Selling at CG Oncology

In other CG Oncology news, Director Leonard E. Post sold 5,000 shares of the firm’s stock in a transaction on Tuesday, September 30th. The shares were sold at an average price of $40.09, for a total value of $200,450.00. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director James Mulay sold 5,903 shares of CG Oncology stock in a transaction dated Thursday, October 9th. The shares were sold at an average price of $43.99, for a total transaction of $259,672.97. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 11,903 shares of company stock worth $501,553.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on CGON. Jones Trading initiated coverage on CG Oncology in a report on Monday, September 8th. They set a “buy” rating and a $50.00 price target for the company. HC Wainwright reaffirmed a “buy” rating and set a $75.00 target price on shares of CG Oncology in a research note on Monday, September 15th. Cantor Fitzgerald reissued an “overweight” rating and issued a $75.00 price target on shares of CG Oncology in a research note on Monday, September 8th. Royal Bank Of Canada raised their price objective on shares of CG Oncology from $53.00 to $61.00 and gave the stock an “outperform” rating in a research report on Monday, November 17th. Finally, Truist Financial set a $62.00 price objective on shares of CG Oncology in a research note on Monday, November 24th. One equities research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $60.58.

CG Oncology Stock Performance

Shares of NASDAQ:CGON opened at $39.84 on Monday. CG Oncology, Inc. has a 52-week low of $14.80 and a 52-week high of $46.01. The business’s 50 day simple moving average is $41.54 and its two-hundred day simple moving average is $34.26. The firm has a market cap of $3.21 billion, a P/E ratio of -19.53 and a beta of 1.29.

CG Oncology (NASDAQ:CGON) last issued its earnings results on Friday, November 14th. The company reported ($0.57) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.57). CG Oncology had a negative return on equity of 21.67% and a negative net margin of 15,945.17%.The company had revenue of $0.16 million for the quarter, compared to analyst estimates of $0.07 million. On average, equities analysts forecast that CG Oncology, Inc. will post -1.31 earnings per share for the current fiscal year.

CG Oncology Profile

CG Oncology, Inc (NASDAQ: CGON) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel antibody-based immunotherapies for the treatment of solid tumor cancers. The company leverages a platform-driven approach to identify and optimize antibody candidates that engage key immune checkpoints and co-stimulatory pathways within the tumor microenvironment. Its pipeline encompasses multiple preclinical programs alongside early-phase clinical trials designed to assess safety, dosing and preliminary anti-tumor activity.

Headquartered in South San Francisco, California, CG Oncology conducts clinical research primarily in the United States, collaborating with leading academic medical centers and contract research organizations to advance its lead candidates.